Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00801489
Title Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin

Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.